Gypenoside A
CAS No. : 157752-01-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $62 | In-stock |
| 10mg | $100 | In-stock |
| 25mg | $160 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N2440 |
| M.Wt: | 899.07 |
| Formula: | C46H74O17 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Gypenoside A is an orally active triterpenoid compound that can be isolated from Gynostemma pentaphyllum. Gypenoside A has anti-inflammatory and antioxidant activities. Gypenoside A also has a certain protective effect on cardiomyocytes and can inhibit apoptosis. Gypenoside A can be used in the research of cardiovascular diseases and inflammation-related diseases[1][2][3].
In Vitro:Gypenoside A (0-10 μM; 24 h) can reduce the secretion of cytokines and chemokines and inhibit the production of ROS in TNF-α/IL-4-treated BEAS-2B cells[1].
Gypenoside A (10-20 μM; 24 h) can increase cell viability and inhibit apoptosis in OGD/R-treated H9c2 cells. The mechanism involves the activation of the AMPK/Foxo1 signaling pathway and a decrease in the expression level of miR-143-3p[2].
In Vivo:Gypenoside A (10-30 mg/kg; intraperitoneal injection; single dose) has an improving effect in a mouse asthma model[1].
Gypenoside A (100 mg/kg; gavage; single dose) can improve hemodynamic parameters, reduce apoptosis and infarct area in myocardial tissue in a rat myocardial ischemia/reperfusion injury model[2].
Pharmacokinetic Analysis in Rats[3]
| Route | Dose (mg/kg) | AUC(0-t) (ng/mL·h) | AUC(0-∞) (ng/mL·h) | t1/2z (h) | CLz/F (L/h/kg) | Vz/F (L/kg) | Cmax (ng/mL) |
| p.o. | 5 | 14.9 | 15.9 | 1.4 | 319.9 | 665.4 | 8.6 |
| i.v. | 1 | 332.9 | 334.3 | 0.8 | 3.0 | 3.3 | 621.9 |